References

uzspbgmu

Учёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. Павлова

The Scientific Notes of the Pavlov University

1607-41812541-8807

Academician I.P. Pavlov First St. Petersburg State Medical University

10.24884/1607-4181-2023-30-3-22-35

uzspbgmu-1011

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Перспективы применения ингибиторов IX и XII изоформ карбоангидразы в онкологии

Prospects for the application of inhibitors of carbonic anhydrase isoforms IX and XII in oncology

https://orcid.org/0000-0002-6421-1208

Калинин

С. А.

Kalinin

S. А.

Калинин Станислав Алексеевич, старший преподаватель кафедры медицинской химии Института химии

Санкт-Петербург

Kalinin Stanislav A., Senior Lecturer ща the Department of Medical Chemistry, Institute of Chemistry

Saint Petersburg

stanislaw.k@mail.ru

Шаронова

Т. В.

Sharonova

Т. V.

Шаронова Татьяна Валерьевна, младший научный сотрудник лаборатории субклеточных технологий с группой онкоэндокринологии

Санкт-Петербург

Sharonova Tatiana V., Junior Research Fellow of the Laboratory of Subcellular Technologies with Oncoendocrinology Group

Saint Petersburg

tat.sharonowa2016@yandex.ru

Малкова

А. М.

Malkova

А. М.

Малкова Анна Михайловна, аспирант

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Malkova Anna M., graduate student

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0002-2709-7282

Агеев

С. В.

Ageev

S. V.

Агеев Сергей Вадимович, специалист по учебно-методической работе, заведующий учебной частью кафедры общей и биоорганической химии

197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Ageev Sergei V., Teaching and Learning Specialist, Head of the Educational Department of the Department of General and Bioorganic Chemistry

6-8, L’va Tolstogo str., Saint Petersburg, 197022

ageev.sergey06@gmail.com

https://orcid.org/0000-0003-2239-2044

Семёнов

К. Н.

Semenov

К. N.

Семёнов Константин Николаевич, доктор химических наук, профессор кафедры общей и биоорганической химии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Semenov Konstantin N., Dr. of Sci. (Chem.), Professor of the Department of General and Bioorganic Chemistry

6-8, L’va Tolstogo str., Saint Petersburg, 197022

knsemenov@gmail.com

https://orcid.org/0000-0002-3717-0471

Шаройко

В. В.

Sharoyko

V. V.

Шаройко Владимир Владимирович, доктор биологических наук, профессор кафедры общей и биоорганической химии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Sharoyko Vladimir V., Dr. of Sci. (Biol.), Professor of the Department of General and Bioorganic Chemistry

6-8, L’va Tolstogo str., Saint Petersburg, 197022

sharoyko@gmail.com

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»РоссияSt Petersburg UniversityRussian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»; Федеральное государственное бюджетное учреждение «Научно-исследовательский институт онкологии имени Н. Н. Петрова» Министерства здравоохранения Российской ФедерацииРоссияSt Petersburg University; Petrov National Medical Research Center for OncologyRussian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияSt Petersburg University; Pavlov UniversityRussian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Тольяттинский государственный университет»РоссияSt Petersburg University; Pavlov University; Tolyatti State UniversityRussian Federation

2023

08112023

3032235

2024

Калинин С.А., Шаронова Т.В., Малкова А.М., Агеев С.В., Семёнов К.Н., Шаройко В.В.

Kalinin S.А., Sharonova Т.V., Malkova А.М., Ageev S.V., Semenov К.N., Sharoyko V.V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.sci-notes.ru/jour/article/view/1011

Изоформы IX и XII карбоангидразы человека играют ключевую роль в поддержании кислотно-основного равновесия в солидных опухолях, формируя благоприятное микроокружение для роста, инвазии и метастазирования опухолевых клеток. В последние несколько лет рядом научных групп опубликованы результаты о том, что ингибирование изоформ IX и XII значительно повышает эффективность классической химиотерапии, позволяет подавлять резистентность опухолевых клеток к химиотерапии и повысить их чувствительность к применяемым препаратам (в т.ч. снижение дозы цитостатиков). В обзоре нами проведен анализ научной литературы о роли изоформ IX и XII карбоангидразы в канцерогенезе и по комбинированному действию ингибиторов карбоангидраз с противоопухолевыми препаратами.

Human carbonic anhydrase isoforms IX and XII play a key role in maintaining acid-base balance in solid tumors, creating a favorable microenvironment for the growth, invasion and metastasis of tumor cells. In the last few years, a number of scientific groups have published results that inhibition of isoforms IX and XII significantly increases the effectiveness of classical chemotherapy, makes it possible to suppress the resistance of tumor cells to chemotherapy and increase their sensitivity to the used drugs (including reducing the dose of cytostatics). In the review, we analyzed the scientific literature on the role of carbonic anhydrase isoforms IX and XII in carcinogenesis and on the combined effect of carbonic anhydrase inhibitors with antitumor drugs.

ингибиторы карбоангидразсульфонамидыонкологические заболевания

carbonic anhydrase inhibitorssulfonamidesoncological diseases

Работа выполнена при поддержке Российского научного фонда (проект № 21-73-20264 «Комплексный подход к разработке адъювантных агентов на основе ингибиторов IX изоформы карбоангидразы человека для комбинированной терапии онкологических заболеваний»).

The work was supported by the Russian Science Foundation (project № 21-73-20264 “The integrated approach to the development of adjuvant agents based on inhibitors IX of human carbonic anhydrase isoform for combination therapy of oncological diseases”.

References1

Neri D., Supuran C. T. Interfering with pH regulation in tumours as a therapeutic strategy // Nature Reviews Drug Discovery. Nature Publishing Group. – 2011. – Vol. 10. – № 10. – P. 767–777.

Neri D., Supuran C. T. Interfering with pH regulation in tumours as a therapeutic strategy // Nature Reviews Drug Discovery. Nature Publishing Group. 2011;10(10):767–777.

Benej M., Pastorekova S., Pastorek J. Carbonic Anhydrase IX: regulation and role in cancer // Subcell. Biochem. – 2014. – Vol. 75. – P. 199–219.

Benej M., Pastorekova S., Pastorek J. Carbonic Anhydrase IX: regulation and role in cancer // Subcell. Biochem. 2014;75:199–219.

Gilmour K. M. Perspectives on carbonic anhydrase // Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. – 2010. – Vol. 157, № 3. – P. 193–197.

Gilmour K. M. Perspectives on carbonic anhydrase // Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. 2010; 157(3):193–197.

McKenna R., Frost S. C. Overview of the carbonic anhydrase family // Sub-cellular biochemistry. United States. – 2014. – Vol. 75. – P. 3–5.

McKenna R., Frost S. C. Overview of the carbonic anhydrase family // Sub-cellular biochemistry. United States. 2014;75:3–5.

Zamanova S., Shabana A. M., Mondal U. K., Ilies M. A. Carbonic anhydrases as disease markers // Expert Opin. Ther. Pat. – 2019. – Vol. 29, № 7. – P. 509–533.

Zamanova S., Shabana A. M., Mondal U. K., Ilies M.A. Carbonic anhydrases as disease markers // Expert Opin. Ther. Pat. 2019;29(7):509–533.

Lomelino C. L., Andring J. T., McKenna R. Crystallography and Its Impact on Carbonic Anhydrase Research // Int. J. Med. Chem. – 2018. – Vol. 2018. – P. 1–21.

Lomelino C. L., Andring J. T., McKenna R. Crystallography and Its Impact on Carbonic Anhydrase Research // Int. J. Med. Chem. 2018;2018:1–21.

Alterio V., Hilvo M., Di Fiore A. et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX // Proc. Natl. Acad. Sci. U. S. A. – 2009. – Vol. 106, № 38. – P. 16233–16238.

Alterio V., Hilvo M., Di Fiore A. et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX // Proc. Natl. Acad. Sci. U. S. A. 2009; 106(38):16233–16238.

Whittington D. A., Waheed A., Ulmasov B. et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells // Proc. Natl. Acad. Sci. U. S. A. – 2001. – Vol. 98, № 17. – P. 9545–9550.

Ilies M. A., Winum J. Y. Carbonic anhydrase inhibitors for the treatment of tumors: Therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XII // Carbonic Anhydrases: Biochemistry and Pharmacology of an Evergreen Pharmaceutical Target. Elsevier Inc. – 2019. – Vol. 2. – P. 331–365.

Ilies M.A., Winum J. Y. Carbonic anhydrase inhibitors for the treatment of tumors: Therapeutic, immunologic, and diagnostic tools targeting isoforms IX and XII // Carbonic Anhydrases: Biochemistry and Pharmacology of an Evergreen Pharmaceutical Target. Elsevier Inc. 2019;2:331–365.

Chiche J., Ilc K., Laferrière J. et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH // Cancer Res. – 2009. – Vol. 69, № 1. – P. 358–368.

Terry S., Faouzi Zaarour R., Hassan Venkatesh G. et al. Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity // Int. J. Mol. Sci. – 2018. – Vol. 19, № 10. – P. 3044–3063.

Terry S., Faouzi Zaarour R., Hassan Venkatesh G. et al. Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity // Int. J. Mol. Sci. 2018;19(10):3044–3063.

Parks S.K., Chiche J., Pouyssegur J. pH control mechanisms of tumor survival and growth // J. Cell. Physiol. United States. – 2011. – Vol. 226, № 2. – P. 299–308.

Parks S. K., Chiche J., Pouyssegur J. pH control mechanisms of tumor survival and growth // J. Cell. Physiol. United States. 2011;226(2):299–308.

Pastorekova S., Gillies R. J. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond // Cancer Metastasis Rev. Cancer and Metastasis Reviews. – 2019. – Vol. 38, № 1–2. – P. 65–77.

Ames S., Pastorekova S., Becker H. M. The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells // Oncotarget. – 2018. – Vol. 9, № 46. – P. 27940–27957.

Raghunand N., Gatenby R. A., Gillies R. J. Microenvironmental and cellular consequences of altered blood flow in tumours // Br. J. Radiol. England. – 2003. – Vol. 76. – P. 11–22.

Raghunand N., Gatenby R. A., Gillies R. J. Microenvironmental and cellular consequences of altered blood flow in tumours // Br. J. Radiol. England. 2003;76:11–22.

Gatenby R. A., Gillies R. J. A microenvironmental model of carcinogenesis // Nat. Rev. Cancer. England. – 2008. – Vol. 8, № 1. – P. 56–61.

Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis // Nat. Rev. Cancer. England. 2008;8(1):56–61.

Riemann A., Rauschner M., Gießelmann M. et al. Extracellular acidosis modulates the expression of Epithelial-Mesenchymal Transition (EMT) markers and adhesion of epithelial and tumor cells // Neoplasia. – 2019. – Vol. 21, № 5. – P. 450–458.

Tonissen K. F., Poulsen S. A. Carbonic anhydrase XII inhibition overcomes P- glycoprotein-mediated drug resistance: A potential new combination therapy in cancer // Cancer Drug Resist. – 2021. – Vol. 4, № 2. – P. 343–355.

Supuran C. T. Advances in structure-based drug discovery of carbonic anhydrase inhibitors // Expert Opin. Drug Discov. Taylor & Francis. – 2017. – Vol. 12, № 1. – P. 61–88.

Supuran C. T. Advances in structure-based drug discovery of carbonic anhydrase inhibitors // Expert Opin. Drug Discov. Taylor & Francis. 2017;12(1):61–88.

Eldehna W. M., Nocentini A., Al-Rashood S. T. et al. Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer // Bioorg. Chem. Elsevier. – 2018. – Vol. 81. – P. 425–432.

El-Gazzar M. G., Nafie N. H., Nocentini A. et al. Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2018. – Vol. 33, № 1. – P. 1565–1574.

Nocentini A., Bua S., Lomelino C. L. et al. Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous dases // ACS Med. Chem. Lett. – 2017. – Vol. 8, № 12. – P. 1314–1319.

Nocentini A., Bua S., Lomelino C. L. et al. Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous bases // ACS Med. Chem. Lett. 2017;8(12):1314–1319.

Supuran C. T. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors // Expert Opin. Investig. Drugs. England. – 2018. – Vol. 27, № 12. – P. 963–970.

Supuran C. T. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors // Expert Opin. Investig. Drugs. England. 2018. Vol. 27(12):963–970.

Kurt B. Z., Dag A., Doğan B. et al. Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma // Bioorg. Chem. Elsevier. – 2019. – Vol. 87. – P. 838–850.

Bonardi A., Falsini M., Catarzi D. et al. Structural investigations on coumarins leading to chromeno[4,3- c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII // Eur. J. Med. Chem. – 2018. – Vol. 146. – P. 47–59.

Bonardi A., Falsini M., Catarzi D. et al. Structural investigations on coumarins leading to chromeno[4,3- c] pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII // Eur. J. Med. Chem. 2018;146:47–59.

Angeli A., Trallori E., Carta F. et al. Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines // ACS Med. Chem. Lett. – 2018. – Vol. 9, № 9. – P. 947–951.

Cadoni R., Pala N., Lomelino C. et al. Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors // ACS Med. Chem. Lett. – 2017. – Vol. 8, № 9. – P. 941–946.

Cadoni R., Pala N., Lomelino C. et al. Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors // ACS Med. Chem. Lett. 2017; 8(9):941–946.

Nocentini A., Lucidi A., Perut F. et al. α-diketocarboxylic acids and their esters act as carbonic anhydrase IX and XII selective inhibitors: rapid-communication // ACS Med. Chem. Lett. American Chemical Society. – 2019. – Vol. 10, № 4. – P. 661–665.

Ivanova J., Leitans J., Tanc M. et al. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors // Chem. Commun. Royal Society of Chemistry. – 2015. – Vol. 51, № 33. – P. 7108–7111.

Ivanova J., Leitans J., Tanc M. et al. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors // Chem. Commun. Royal Society of Chemistry. 2015; 51(33):7108–7111.

Coviello V., Marchi B., Sartini S. et al. 1,2-benzisothiazole derivatives bearing 4-, 5-, or 6- alkyl/arylcarboxamide moieties inhibit Carbonic Anhydrase Isoform IX (CAIX) and cell proliferation under hypoxic conditions // J. Med. Chem. – 2016. – Vol. 59, № 13. – P. 6547–6552.

Bua S., Lomelino C. L., Murray A. B. et al. “a Sweet Combination”: developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII // J. Med. Chem. – 2020. – Vol. 63, № 1. – P. 321–333.

Bua S., Lomelino C. L., Murray A. B. et al. “A sweet combination”: developing saccharin and acesulfame K structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII // J. Med. Chem. 2020; 63(1):321–333.

Riemann A., Güttler A., Haupt V. et al. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity // Oncol. Res. – 2018. – Vol. 26. – № 2. – P. 191–200.

Riemann A., Güttler A., Haupt V. et al. Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity // Oncol. Res. 2018;26(2):191–200.

Bernardino R. L., Dias T. R., Moreira B. P. et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells // FEBS J. England. – 2019. – Vol. 286, № 7. – P. 1393–1406.

McDonald P. C., Chia S., Bedard P. L. et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors // Am. J. Clin. Oncol. – 2020. – Vol. 43, № 7. – P. 484–490.

McDonald P. C., Chia S., Bedard P. L. et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors // Am. J. Clin. Oncol. 2020;43(7):484–490.

Gieling R. G., Babur M., Mamnani L. et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts // J. Med. Chem. – 2012. – Vol. 55, №11. – P. 5591–5600.

Gieling R. G., Babur M., Mamnani L. et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts // J. Med. Chem. 2012; 55(11):5591–5600.

Bryant J. L., Gieling R. G., Meredith S. L. et al. Novel carbonic anhydrase IX-targeted therapy enhances the antitumour effects of cisplatin in small cell lung cancer // Int. J. cancer. United States. – 2018. – Vol. 142, № 1. – P. 191–201.

Cuffaro D., Nuti E., Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2020. – Vol. 35, № 1. – P. 1906–1922.

Cuffaro D., Nuti E., Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors // J. Enzyme Inhib. Med. Chem. Taylor & Francis. 2020;35(1):1906–1922.

Supuran C. T. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors // Expert Opin. Investig. Drugs. Taylor & Francis. – 2021. – Vol. 30, № 12. – P. 1197–1208.

Andreucci E., Ruzzolini J., Peppicelli S. et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy // J. Enzyme Inhib. Med. Chem. Taylor & Francis. – 2019. – Vol. 34, № 1. – P. 117–123.

Boyd N. H., Walker K., Fried J. et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo // JCI Insight. – 2017. – Vol. 2, № 24. – P. 1–16.

Boyd N. H., Walker K., Fried J. et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo // JCI Insight. 2017;2(24):1–16.

Van Kuijk S. J., Gieling R. G., Niemans R. et al. The sulfamate small molecule CAIX inhibitor S4 modulates doxorubicin efficacy // PLoS One. – 2016. – Vol. 11, № 8. – P. 1–14.

Van Kuijk S. J., Gieling R. G., Niemans R. et al. The sulfamate small molecule CAIX inhibitor S4 modulates doxorubicin efficacy // PLoS One. 2016;11(8):1–14.

Ward C., Meehan J., Mullen P. et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models // Oncotarget. – 2015. – Vol. 6, № 28. – P. 24856–24870.

McDonald P. C., Chafe S. C., Brown W. S. et al. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia // Gastroenterology. – 2019. – Vol. 157, № 3. – P. 823–837.

Kleeff J., Korc M., Apte M. et al. Pancreatic cancer // Nat. Rev. Dis. Prim. Macmillan Publishers Limited. – 2016. – Vol. 2. – P. 1–23.

Kleeff J., Korc M., Apte M. et al. Pancreatic cancer // Nat. Rev. Dis. Prim. Macmillan Publishers Limited. 2016;2:1–23.

Lee K. E., Spata M., Bayne L. J. et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia // Cancer Discov. – 2016. – Vol. 6, № 3. – P. 256–269.

Lee K. E., Spata M., Bayne L. J. et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia // Cancer Discov. 2016;6(3):256–269.

Petrenko M., Güttler A., Funtan A. et al. Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells // Chem. Biol. Interact. – 2021. – Vol. 333. – P. 109326–109335.

Hedlund E. M. E., McDonald P. C., Nemirovsky O. et al. Harnessing induced essentiality: Targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts // Cancers (Basel). – 2019. – Vol. 11, № 7. – P. 1002–1020.

Chiche J., Brahimi-Horn M.C., Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer // J. Cell. Mol. Med. – 2010. – Vol. 14, № 4. – P. 771–794.

Chiche J., Brahimi-Horn M. C., Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer // J. Cell. Mol. Med. 2010;14(4):771–794.

Bellot G., Garcia-Medina R., Gounon P. et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains // Mol. Cell. Biol. – 2009. – Vol. 29, № 10. – P. 2570–2581.

Bellot G., Garcia-Medina R., Gounon P. et al. Hypoxia-Induced Autophagy Is Mediated through Hypoxia- Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains // Mol. Cell. Biol. 2009;29(10):2570–2581.

Chafe S. C., Vizeacoumar F. S., Venkateswaran G. et al. Genome-wide synthetic lethal screen unveils novel CAIXNFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors // Sci. Adv. – 2021. – Vol. 7, № 35. – P. 1–16.

The authors declare that there are no conflicts of interest present.